Introduction
Identification of tumor antigens in the 1990s (1) paved the way for detection of tumor antigen-specific T cells in cancer patients (2, 3) . It was found that tumor-reactive T cells coexisted with cancer cells in tumors and draining lymph nodes without causing tumor regression (3) . At least 3 factors were suggested to be responsible. First, the expansion of tumor-specific T cells may not be optimal. This notion led to the development of a therapeutic cancer vaccine but with only limited success until recently, when neoantigen-based individual cancer vaccines were developed (4) (5) (6) . Second, Tregs have been shown to be expanded in cancer patients and are enriched in cancer lesions (7) . Depletion of Tregs has led to increased tumor immunity in mice (8, 9) . In anti-CTLA-4 antibody-treated tumor-bearing mice, Treg depletion in tumor lesion correlates with therapeutic response (10, 11) . However, the impact of anti-CTLA-4 antibody therapy is tempered by autoimmune side effects (12) . Third, cancer-reactive T cells are functionally exhausted or anergic (2) in the tumor microenvironment (TME). Checkpoint blockade therapies such as anti-PD-1 therapy have shown therapeutic effects to different cancer types (13, 14) . However, many cancer types are resistant to anti-PD-1 therapy, and for those that respond, the overall responding rates remain low (15) . Thus, development of novel strategies to enhance the efficacy of cancer immunotherapy is highly desired.
IL-27 is an IL-12 family cytokine that is known to inhibit autoimmune Th17 and Th2 responses (16, 17) . Accumulating evidence from animal studies has indicated that both endogenous (18, 19) and exogenous (20) (21) (22) IL-27 inhibit tumor growth. A variety of mechanisms including enhancement of tumor-specific T cell responses (20, 21) have been proposed. Our previous study (23) has revealed that IL-27 programs CD8
+ effector T cells into
Tumor-induced expansion of Tregs is a significant obstacle to cancer immunotherapy. However, traditional approaches to deplete Tregs are often inefficient, provoking autoimmunity. We show here that administration of IL-27-expressing recombinant adeno-associated virus (AAV-IL-27) significantly inhibits tumor growth and enhances T cell responses in tumors. Strikingly, we found that AAV-IL-27 treatment causes rapid depletion of Tregs in peripheral blood, lymphoid organs, and -most pronouncedly -tumor microenvironment. AAV-IL-27-mediated Treg depletion is dependent on IL-27 receptor and Stat1 in Tregs and is a combined result of CD25 downregulation in Tregs and inhibition of IL-2 production by T cells. In combination with a GM-CSF vaccine, AAV-IL-27 treatment not only induced nearly complete tumor rejection, but also resulted in amplified neoantigen-specific T cell responses. AAV-IL-27 also dramatically increased the efficacy of anti-PD-1 therapy, presumably due to induction of PD-L1 in T cells and depletion of Tregs. Importantly, AAV-IL-27 therapy did not induce significant adverse events, partially due to its induction of IL-10.
In a plasmacytoma mouse model, we found that IL-10 was required for AAV-IL-27-mediated tumor rejection. Thus, our study demonstrates the potential of AAV-IL-27 as an independent cancer therapeutic and as an efficient adjuvant for cancer immunotherapy.
Downloaded from http://insight.jci.org on April 6, 2018. https://doi.org/10.1172/jci.insight.98745 a unique T effector phenotype featured by producing both IFN-γ and IL-10, which not only enhances T cell survival in TME, but also promotes T cell memory. In addition, we have also found that endogenous IL-27 is also required for cancer vaccine response (24) . The unique functions of IL-27 suggest that developing IL-27-based cancer immunotherapy may lead to enhancing tumor immunity while inhibiting autoimmunity. Although the role of IL-27 in tumor immunity has been appreciated for more than 10 years, developing IL-27 into a therapeutic to enhance tumor immunity has not been well achieved (25) . Recombinant adenoassociated virus vectors (rAAV) are quickly establishing themselves as highly versatile gene delivery agents for gene therapy. The relatively low immunogenicity and toxic effects make rAAV arguably the gene therapy vector of choice for human clinical trials (26) . In this study, we used an AAV system to systemically deliver IL-27 (AAV-IL-27) to treat mice with tumors. We show here that administration of AAV-IL-27 significantly inhibited tumor growth and enhances T cell responses in tumors. Strikingly, we found that AAV-IL-27 treatment caused rapid depletion of Tregs in peripheral blood, lymphoid organs, and -most pronouncedly -in TME. AAV-IL-27-mediated Treg depletion is dependent on IL-27 receptor and Stat1 in Tregs and is a combined result of CD25 downregulation in Tregs and inhibition of T cell IL-2 production. In combination with a GM-CSF vaccine, AAV-IL-27 treatment not only induced nearly complete tumor inhibition and long-term survival of mice, but also resulted in amplified tumor neoantigen-specific T cell responses. Moreover, we found that AAV-IL-27 also dramatically increased the efficacy of anti-PD-1 therapy. Importantly, AAV-IL-27 therapy did not induce significant adverse events, partially due to its induction of IL-10. In a plasmacytoma mouse model, we found that IL-10 was required for AAV-IL-27-mediated tumor rejection. Thus, our study demonstrates the potential of AAV-IL-27 as an independent cancer therapeutic and as an efficient adjuvant for cancer immunotherapy.
Results

IL-27 gene therapy inhibits tumor growth.
To determine if IL-27 can be used as a potential cancer therapeutic, we generated rAAV vectors that express IL-27 (AAV-IL-27) and the control AAV vector (AAV-ctrl) without the IL-27 cDNA. I.m. injection of 2 × 10 11 DNase resistance particle (DRP)/mouse of AAV-IL-27 achieved high and sustained IL-27 production in the peripheral blood of mice ( Figure 1A ). We then tested if AAV-IL-27 can be used to treat mice with B16 melanoma. First, we injected B16.F10 cells (2 × 10 5 / mouse) into C57BL/6 mice s.c., and 4 days after tumor cell injection, mice were injected with AAV-IL-27 or AAV-ctrl virus i.m. at a dose of 2 × 10 11 DRP/mouse. As shown in Figure 1B , while B16.F10 tumors grew progressively in AAV-ctrl virus-treated mice, their growths were significantly inhibited in AAV-IL-27-treated mice. However, AAV-IL-27 treatment failed to inhibit B16 tumor growth in Il27ra -/-( Figure 1C ) and Rag1 -/-( Figure 1D ) mice, suggesting that the tumor-inhibiting effect was IL-27 specific and not directed to tumor cells, but rather through activation of host immune responses. We also injected B16. F10 cells into B6 mice i.v., and 4 days later, mice were treated with a single dose (2 × 10 11 DRP/mouse) of AAV-IL-27 or AAV-ctrl virus i.m. As demonstrated in Figure 1E , mice receiving AAV-IL-27 treatment had significantly reduced tumor foci in the lungs compared with mice treated with AAV-ctrl virus. Correspondingly, the lung weights of the AAV-IL-27-treated mice were significantly reduced. Similarly, we found that AAV-IL-27 therapy was also effective in inhibiting the growth of MC38 colon tumors ( Figure  1F ) and EO771 breast tumors ( Figure 1G ) in C57BL/6 mice, and of J558 plasmacytoma tumors ( Figure  1H ) in BALB/c mice. Thus, AAV-IL-27 is an effective immunotherapeutic that inhibits the growth of a broad spectrum of cancer types in experimental mouse tumor models.
AAV-IL-27 therapy induces depletion of Tregs and enhances T cell effector functions.
To determine if AAV-IL-27 treatment altered TME, we examined the cellular components of tumor-infiltrating leukocytes in B16 tumors from AAV-IL-27-or AAV-ctrl virus-treated mice using flow cytometry. As shown in Figure 2A , AAV-IL-27 treatment increased the percentage of CD45 + leukocytes in tumors. In the myeloid cell compartment, the relative portions of DCs (CD11b Figure 2B ). Moreover, we found that DC and myeloid cells in tumors from AAV-IL-27-treated mice had increased expression of MHC class II ( Figure 2C ). AAV-IL-27 treatment also enhanced tumor infiltration of NK cells ( Figure 2D ) and expression of Granzym B ( Figure 2E ) and Perforin ( Figure 2F ) in NK cells. Finally, we found that AAV-IL-27 treatment significantly reduced tumor infiltration of CD19 + B cells while it enhanced the infiltration of CD3 + T cells ( Figure 2G ). Since IL-27 is known to enhance Th1/Tc1 responses, we examined if T cell responses differed in B16 tumors from AAV-IL-27-and AAV-ctrl virus-treated mice. As shown in Figure 3A , we found that AAV-IL-27 treatment significantly increased the infiltration of both CD4 + and CD8 + T cells into B16 tumors. The percentages of IFN-γ-producing CD4 + and CD8 + T cells in B16 tumors were also significantly increased ( Figure 3B ). Moreover, tumor-infiltrating CD8 + T cells from AAV-IL-27-treated mice also had increased expression of Granzyme B ( Figure 3C ) and Perforin ( Figure 3D ). Strikingly, we found that FoxP3 + Tregs were greatly reduced in spleens and B16 tumors of AAV-IL-27-treated mice ( Figure 3E ). Similarly, we found that mice with MC38 colon tumors treated with AAV-IL-27 also showed increased tumor infiltration of CD4 + and CD8 + T cells ( Figure 3F ), increased percentages of IFN-γ-producing CD4 + and CD8 + T cells ( Figure 3G ), and greatly reduced Tregs in both spleen and tumors ( Figure 3H ). Thus, AAV-IL-27 treatment enhances T cell effector functions in tumors and depletes Tregs in peripheral lymphoid organs and tumors.
AAV-IL-27 treatment inhibits IL-2R (CD25) expression in Tregs and IL-2 production by T cells.
We found that AAV-IL-27-mediated Treg depletion was a rapid process. By day 8 after AAV-IL-27 treatment, Tregs were already depleted in peripheral blood ( Figure 4A ). In spleens of AAV-IL-27-treated mice, we found that AAV-IL-27 treatment downregulated IL-2 receptor (CD25) expression, such that the CD25 +
FoxP3
+ Treg population was gradually reduced over time ( Figure 4B ). Since IL-2 is known to induce CD25 expression in T cells (27) , and IL-27 is known to inhibit T cell secretion of IL-2 (28, 29), we examined if AAV-IL-27 treatment reduced IL-2 production by T cells. We found that, in AAV-IL-27-treated mice, IL-2 production by spleen T cells ( Figure 4C ) and tumor-infiltrating T cells ( Figure 4D ) was significantly reduced but was still maintained at significant levels, especially in spleens ( Figure 4C ). To test if heightened IL-2 signal prevents AAV-IL-27-mediated Treg depletion, we coinjected AAV-IL-2 with AAV-IL-27 and found that AAV-IL-2 treatment greatly enhanced the expression of CD25 in Tregs (Figure 4 , E and F) and prevented their depletion in peripheral blood ( Figure 4E ) and spleen ( Figure 4F ). Thus, strengthening IL-2 signaling could upregulate CD25 expression in Tregs and prevent AAV-IL-27-mediated Treg depletion. 
AAV-IL-27-mediated Treg depletion is dependent on IL-27R-Stat1 signaling in Tregs. Unlike in WT mice, AAV-IL-27 treatment of IL-27Rα
-/-mice did not cause Treg reduction in spleens ( Figure 5A ) and tumors ( Figure 5B ). Similarly, AAV-IL-27 treatment of Stat1 -/-mice also failed to deplete Tregs ( Figure 5C ). We further determined if the effect was Treg intrinsic or extrinsic using a mixed BM chimera approach. Briefly, BM cells from IL-27Rα -/-mice (CD45.2 + ) were mixed with BM cells from CD45.1 + C57BL/6 mice at a 1:1 ratio and were injected into lethally irradiated B6 recipients to generate mixed BM chimeras. Twelve weeks after BM transfer, BM chimeric mice were injected with 0.2 × 10 6 B16.F10 cells per mouse s.c. and were treated with AAV-IL-27 or AAV-ctrl viruses 4 days later. As shown in Figure 5D Figure 5E ), while CD45.2 + Tregs were resistant to AAV-IL-27-mediated Treg deletion. These results together suggest that IL-27 signaling in Tregs mediates their depletion in AAV-IL-27-treated mice.
AAV-IL-27 treatment significantly enhances cancer vaccine efficacy. Tumor-(30) and vaccine-induced (31) expansion of Tregs is a significant obstacle to successful cancer immunotherapy. Since AAV-IL-27 treatment dramatically reduced Tregs in both peripheral lymphoid organs and tumors, we tested if AAV-IL-27 treatment could enhance cancer vaccine efficacy. We infected B16.F10 tumor cells with a lentivirus expressing GM-CSF or a control lentivirus, and we generated GM-CSF-secreting B16 tumor cells (B16-GM-CSF) and control B16 cells (B16-ctrl). As expected, tumors established by B16-GM-CSF cells grew much slower compared with B16-ctrl cells ( Figure 6A ). However, we observed significant expansion of Tregs in mice with B16-GM-CSF tumors ( Figure 6B ). To determine if AAV-IL-27 and B16-GM-CSF vaccines had synergy in inhibiting tumor growth, C57BL/6 mice were immunized with irradiated B16-GM-CSF or B16-ctrl cells; 1 week later, the immunized mice were challenged with 2 × 10 5 /mouse of B16.F10 cells s.c. Four days after live tumor cell injection, mice were also treated with either AAV-IL-27 or AAV-ctrl vectors. We found that the combinations of AAV-IL-27/B16-ctrl-or B16-GM-CSF/AAV-ctrl-treated mice had significant reduced tumor growth ( Figure 6C ) compared with AAV-ctrl/B16-ctrl-treated mice. However, most significant tumor growth inhibition ( Figure 6C ) and prolonged survival ( Figure 6D ) were observed in AAV-IL-27/B16-GM-CSF combination-treated mice. As expected, Treg depletion was only observed in mice receiving AAV-IL-27 treatment ( Figure 6E ). Recently, the whole genome/exosome sequencing of B16.F10 tumor cells has identified 21 neoantigens (32) . We used IFN-γ ELISPOT assay to evaluate T cell responses to those neoantigens to determine if AAV-IL-27/GM-CSF combination therapy induced more tumor antigen-specific T cells. As shown in Figure 6F , we found that spleens of AAV-IL-27/B16-GM-CSF-treated mice had globally enhanced T cell responses against those mutated peptides compared with AAV-ctrl/B16-GM-CSF-treated or other combination therapies. Thus, AAV-IL-27 treatment not only enhanced cancer vaccine efficacy, but also greatly boosted tumor antigen-specific T cell responses.
AAV-IL-27 therapy overcomes anti-PD-1 resistance. IL-27 was shown to induce the expression of programmed death-ligand 1 in T cells, which caused T cell tolerance via interaction with PD-1 on T cells (33) . We found that CD4 + and CD8 + T cells from blood, spleen, and tumors receiving AAV-IL-27 treatment indeed upregulated PD-L1 expression ( Figure 7A ). Induction of PD-L1 expression was IL-27R dependent, since AAV-IL-27 treatment failed to induce T cell expression of PD-L1 in Il27ra -/-mice ( Figure 7B ). Moreover, we found that AAV-IL-27-mediated induction of PD-L1 was compromised in Stat1 -/-mice ( Figure  7C ), which is consistent with a critical role for Stat1 in IL-27 signaling (34).
To determine if IL-27-induced PD-L1 expression in T cells prevented the effectiveness of IL-27 therapy, C57BL/6 mice were injected with 2 × 10 5 B16.F10 cells s.c. and received the following treatments on day 4: AAV-ctrl virus + control mAb; AAV-ctrl virus + anti-PD-1; AAV-IL-27 virus + control mAb; or AAV-IL-27 virus + anti-PD-1. Antibodies were injected into mice at a dose of 300 μg/mouse i.p. at 3-day intervals starting on day 4. As shown in Figure 7D , mice treated with AAV-IL-27 + control mAb showed significantly reduced tumor growth compared with mice treated with AAV-ctrl virus + control mAb or AAV-ctrl virus + anti-PD-1. Most significant inhibition of tumor growth was observed in mice treated with AAV-IL-27 + anti-PD-1 ( Figure 7D ). Overall, AAV-IL-27/anti-PD-1 combination therapy resulted in tumor-free survival in 50% of mice treated ( Figure 7E ). As expected, depletion of Tregs was only observed in groups of mice receiving AAV-IL-27 ( Figure 7F ). We used a similar regimen to treat mice with J558 tumors. As shown in Figure 7G , we found that J558 tumors grew progressively in mice treated with AAVctrl + ctrl Ab and AAV-ctrl + anti-PD-1; while in AAV-IL-27 + ctrl Ab-treated mice, tumors grew progressively, initially followed by significant regression. However, tumors eventually grew back in some mice from this group. In AAV-IL-27 + anti-PD-1-treated mice, tumors first grew into large masses, followed by complete regression ( Figure 7G ). Thus, in 2 tumor models that are resistant to anti-PD-1 therapy, we found that IL-27 gene therapy and anti-PD-1 combination could induce complete tumor rejection. The role of IL-10 in AAV-IL-27-mediated antitumor activity and adverse events. IL-27 is known to induce IL-10 production by T cells (35); we have previously reported that IL-27 promotes T cells to produce IL-10 in vivo and that IL-10 production is critical for the antitumor activity of T cells in the J558 tumor model (23, 36) . We first tested if AAV-IL-27 therapy induced IL-10 production in T cells in the treated mice. As shown in Figure  8A , AAV-IL-27 treatment induced significant numbers of IL-10 + CD4 + and CD8 + T cells in spleens. In B16 tumors, AAV-IL-27 treatment resulted in the depletion of IL-10-producing Tregs, while it induced IL-10 production in effector CD4 + and CD8 + T cells ( Figure 8B ). In the B16 tumor model ( Figure 8C ), we found that AAV-IL-27 treatment significantly inhibited tumor growth in both IL-10 -/-and WT mice, but with a slightly increased efficacy in IL-10 -/-mice compared with its action in WT mice. In the plasmacytoma J558 tumor model, while WT mice were highly susceptible to AAV-IL-27 therapy, we found that IL-10 -/-mice were less responsive to AAV-IL-27 therapy ( Figure 8D) ; as a result, the majority of mice eventually succumbed to tumor growth ( Figure 8E ). Thus, IL-10 was required for AAV-IL-27-mediated antitumor activity in the J558 tumor model and was not required in the B16 model. Systemic depletion of Tregs raised a concern of developing autoimmune diseases in mice treated with AAV-IL-27. This concern is especially valid since IL-27 transgenic mice have been shown to develop Scurfylike diseases (37) . However, we did not find any symptoms of autoimmune diseases in AAV-IL-27-treated BALB/c mice that rejected J558 tumors. We further examined if mice developed pathology at a histological level in AAV-IL-27-treated WT and IL-10 -/-mice. As shown in Figure 9A , at 2 months after treatment, we did not find inflammatory lesions in the heart, lung, liver, pancreas, kidney, or colon in AAV-IL-27-treated WT mice. However, in AAV-IL-27-treated IL-10-deficient mice, we found perivascular inflammatory lesions in the liver but not in other organs ( Figure 9A ). To further understand if perivascular inflammatory lesions in the liver are IL-27 therapy specific, we treated more WT and IL-10 -/-BALB/c mice with AAV-IL-27 or AAV-ctrl virus, and we found that only AAV-IL-27-treated IL-10 -/-mice developed liver inflammatory lesions 2 months later ( Figure 9, B and C) . Thus, IL-10 appears to be a significant contributor to the protection of liver inflammation in AAV-IL-27-treated mice. 
Discussion
In this study, we have developed an innovative and effective gene therapy (i.e., using AAV-IL-27 to treat mice with tumors). We found that monotherapy with AAV-IL-27 significantly inhibited the growth of a broad spectrum of cancer types in experimental mouse models. In combination with a GM-CSF vaccine, AAV-IL-27 treatment induced nearly complete tumor inhibition and long-term survival of mice. Moreover, we found that AAV-IL-27 also dramatically increased the efficacy of anti-PD-1 therapy.
A number of indications suggest that AAV-IL-27-induced T cell response plays key role in its antitumor efficacy. First, we found that AAV-IL-27 therapy only showed efficacy in immune-competent mice but not in Rag1-deficient mice lacking T and B lymphocytes. Second, through the analysis of tumor-infiltrating leukocytes, we found that AAV-IL-27 therapy enhanced T cell, but not B cell, infiltration into tumors, and tumor-infiltrating CD8 + T cells and conventional CD4 + T cells had increased effector functions. Third, we found that AAV-IL-27 therapy also increased DC and NK cell infiltration into tumors. Tumor-infiltrating DCs upregulated MHC class II, and NK cells expressed more Perforin and Granzyme B, suggesting that NK-mediated killing of tumor cells and DC-mediated cross-priming of T cells play important roles in AAV-IL-27-mediated T cell response. Fourth, in mice treated with AAV-IL-27 and GM-CSF vaccine, neoantigen-specific T cell responses were greatly enhanced. Fifth and most strikingly, we found that AAV-IL-27 treatment had a potent effect on depletion of Tregs in peripheral lymphoid organs and, more pronouncedly, in tumors, which could further boost T cell responses. While the above observations are consistent with some of the known functions of IL-27 in tumor immunity (20) (21) (22) , to our knowledge, this study is the first demonstration that therapeutic application of IL-27 causes systemic Treg depletion, which has a significant impact on antitumor T cell responses and cancer immunotherapy.
A previous study (37) has revealed that, in IL-27 transgenic mice, Tregs were found to be deleted, and inhibition of IL-2 production by T cells was considered to be the mechanism responsible for Treg depletion in IL-27 transgenic mice (37) . However, in this study, we found that reduction of IL-2 does not fully explain AAV- IL-27-mediated Treg depletion, since we found that AAV-IL-27-mediated inhibition of IL-2 production was not dramatic, especially in peripheral lymphoid organs (Figure 4 ). Experiments involving mixed BM chimera and gene-deficient mice clearly suggested that AAV-IL-27-mediated Treg depletion depended on IL-27R and Stat1 signaling in Tregs ( Figure 5 ). Since AAV-IL-27 therapy downregulates CD25 expression in Tregs ( Figure  4) , we consider that inhibition of IL-2 signaling in Tregs by IL-27 is the major mechanism for AAV-IL-27-mediated Treg depletion. Mechanistically, IL-27-mediated activation of Stat1 is known to induce the expression of Socs3 (29); Socs3 can inhibit IL-2-induced activation of Jak1 (38) , leading to compromised Stat5 activation and subsequent CD25 expression (39) . Indeed, expression of Socs3 in Tregs has been shown to inhibit Treg proliferation, survival, and effector functions (40) . Heightened IL-2 signaling can prevent AAV-IL-27-mediated Treg depletion, suggesting that this mechanism is active when IL-2 signaling is low. More complete inhibition of IL-2 in tumors explains why depletion of Tregs is more complete in TME (Figure 4) .
Tumor-induced expansion of Tregs is a significant obstacle to successful cancer immunotherapy (30) . Vaccines can prime T cell responses to tumor antigens. However, vaccination is usually accompanied by the expansion of Tregs (31), which can limit the expansion of tumor antigen-specific T cells. GM-CSF-secreting tumor vaccine is a potent inducer of antitumor T cell responses (41) . In this study, we found that it had a similar efficacy of AAV-IL-27 monotherapy. However, these 2 therapeutic together have potent synergy in inducing antitumor T cell responses to neoantigens in B16 tumors, leading to long-term survival of mice. These data suggest that the Treg-depletion ability of AAV-IL-27 and the ability of T cell priming by GM-CSF vaccine are probably an ideal combination for cancer immunotherapy.
Another significant observation in this study is that AAV-IL-27 enhances cancer sensitivity to anti-PD-1 therapy (Figure 7) . The dramatic synergy of the AAV-IL-27 and anti-PD-1 therapy can be explained based on the following observations. First, AAV-IL-27 induces T cell infiltration into tumors (Figure 2 and Figure 3 ), which is considered to be a prerequisite for PD-1 blockade therapy to work (42) . Second, AAV-IL-27 induces PD-L1 by a largely Stat1-dependent mechanism ( Figure 7 , A-C). Since PD-L1-PD-1 interaction is known to limit T cell effector functions (33, 42) , PD-1 blockade can remove the limitation of AAV-IL-27-mediated PD-L1 induction in T cells, leading to rejuvenated T cell effector functions and the control of tumor growth. Interestingly, a recent study suggests that PD-L1 expression in host immune cells is more related to cancer sensitivity to anti-PD-L1 therapy (43) . Thus, our results suggest that induction of PD-L1 in T cells by IL-27 contributes to tumor sensitivity to anti-PD-1 therapy. Third, AAV-IL-27 reduces Tregs in both TME and lymphoid organs in an IL-27R-and Stat1-dependent manner. Tregs in the TME have been shown to contribute to anti-PD-1 resistance (44) . Thus, our data provide a compelling rationale for combination therapy using AAV-IL-27 and anti-PD-1. Current strategies to deplete Tregs to promote antitumor immunity have been met with considerably challenges. On one hand, IL-2 and diphtheria toxin fusion protein could target CD25 + T cells, but they were often found to be inefficient in depleting Tregs in a human trial (45) . On the other hand, experimental studies in mice have shown effective depletion of Tregs in adult mice but lead to severe and even lethal autoimmune diseases (46) . Our data presented herein offers a new approach that can effectively deplete Tregs without causing significant adverse events. We consider the following mechanisms operative in preventing autoimmunity in AAV-IL-27-treated mice. First, AAV-IL-27-mediated Treg depletion is incomplete in lymphoid organs, and the residual Tregs may be sufficient to prevent the development of autoimmunity. Second, AAV-IL-27 can directly inhibit RMP1-14) or an isotype-matched control antibody (2A3) at 3-day intervals for up to 4 times. Tumor volume changes (D, n = 5/group), mice survival (E, n = 8-11/group), and Treg numbers in tumors (F) were examined. Data are expressed as mean ± SEM and represent 3 experiments with similar results. *P < 0.05, **P < 0.01, ***P < 0.001 by 1- way ANOVA (D, F, G) or log-rank test (E). (G) Synergy of anti-PD-1 and AAV-IL-27 in treating mice with plasmocytoma J558 tumors. J558 cells (5 × 10 6 ) were injected into each BALB/c mouse s.c. Four days later, mice were treated with AAV-IL-27 or AAV-ctrl vectors i.m. Starting on day 4, mice were also treated with 300 μg/mouse of anti-PD-1 (RMP1-14) or an isotype-matched control antibody (2A3) at 3-day intervals for up to 4 times. Five mice per group were used for this study. Data are expressed as mean ± SEM and represent 3 experiments with similar results. ***P < 0.001 by 1-way ANOVA.
autoimmune Th2 and Th17 responses via blocking the expression of transcription factors GATA-3 (Th2) and RoRγτ (Th17) (16, 17) and can induce a number of inhibitory pathways in T cells (47) , which may potentially prevent the development of autoimmunity. We recently showed that AAV-IL-27 therapy could block the development of autoimmune colitis by induction of PD-L1 (48) . Third and most likely, AAV-IL-27-induced IL-10-producing T cells play a role in preventing adverse events. IL-10 is a major cytokine that defines a major subset of Tregs and plays a critical role in Treg function. By promoting IL-10 production in effector T cells, AAV-IL-27 therapy may have bypassed the need for Tregs in protection against autoimmune adverse events. Although, at this stage, we are not sure if the observed liver inflammation in AAV-IL-27-treated IL-10 -/-mice ( Figure 9 ) was due to autoimmunity or direct toxicity of excessive IL-27, the fact that the liver inflammation was not observed in WT mice suggests a key role for IL-10 in preventing adverse events related to AAV-IL-27 therapy. In addition to preventing liver inflammation, our data ( Figure 8 ) also suggest that AAV-IL-27-induced IL-10 may contribute to antitumor activity in at least some tumor models. This observation is consistent with the promising clinical trial results using recombinant IL-10 to treat cancer patients (49) . Thus, AAV-IL-27-induced IL-10 could play dual roles in cancer immunotherapy: preventing adverse events and promoting antitumor immunity.
While some studies (37, 50) , including the current study, report a role of IL-27 in limiting Treg population, there are other studies (51) (52) (53) that suggest that IL-27 does not limit Treg populations but enhances the inhibitory functions of Tregs. These seemingly controversial results reflect the pleiotropic roles of IL-27 and could be explained by IL-27 dose and the presence of IL-2 signaling in experimental systems. Treg depletion occurs in IL-27 transgenic mice and mice receiving AAV-IL-27 therapy, suggesting that depletion of Tregs by IL-27 probably requires higher doses of IL-27, which is not present under physiological conditions and the majority of pathological conditions. Additionally, IL-2 was used in Treg cultures in in vitro studies. In systems where Tregs are exposed to excessive IL-2, IL-27 does not inhibit Treg homeostasis due to IL-2 signaling in Tregs counterreacting with the IL-27 signaling, as suggested by this study. Thus, we predict that Treg depletion by IL-27 could occur in settings where IL-27 level is high, while IL-2 signaling is low, which is the case in tumors. Because AAV-IL-27 therapy depletes Tregs while IL-2 signaling prevents IL-27-mediated Treg depletion, AAV-IL-27 and IL-2 combination therapy should be avoided, despite the fact that IL-27/IL-2 synergy in tumor immunotherapy has been reported (54) .
Taken together, this study revealed new approaches of cancer immunotherapy by combining IL-27 administration and cancer vaccination or PD-1 blockade. The new approaches address all 3 restraining factors for cancer immunotherapy: First, through massive reduction of Tregs, active immune suppression during T cell activation and effector functions are removed, without causing significant adverse events. Second, by combination with cancer vaccines, we can optimally stimulate and expand tumor-specific T cells. Third, IL-27 therapy enhances cancer sensitivity to anti-PD-1 therapy by induction of T cell infiltration, PD-L1 expression, and Treg reduction, thereby rejuvenating T cells. Thus, our current study demonstrates the potential of AAV-IL-27 as an independent cancer therapeutic and efficient adjuvant for cancer vaccination or checkpoint blockade therapy.
Methods
Mice and tumor establishment. C57BL/6, CD45.1 + C57BL6, BALB/c, IL10 -/-BALB/c, IL10 -/-C57BL/6, Rag1 -/-, and IL27rα -/-mice were purchased from The Jackson Laboratory and were maintained in the animal facilities of the Ohio State University. Stat1 -/-BALB/c mice have been described previously (55) . B16.F10 melanoma, MC38 colon tumor, and EO771 breast tumor cells were originally obtained from ATCC and used after a few passages in vitro. Plasmacytoma J558 cells have been described previously (23, 24) . These cancer cells were maintained in RPMI 1640 medium (Gibco) supplemented with 100 μg/ ml penicillin, 100 μg/ml streptomycin, and 5% FBS (Gibco). To establish tumors in mice, indicated numbers of cancer cells were injected s.c. or intramammarily into mice in 100 μl of PBS. The length (i) and width (ii) of tumors were measured using a digital caliper every 2 or 3 days. The tumor volume was cal- Production of rAAVs. rAAV-IL-27 and rAAV-IL-2 were produced as we previously described (48) or produced by Obio technology Corp. Briefly, IL-27 or IL-2 cDNA was inserted into an AAV carrier vector under the control of the CMV-chicken β-actin hybrid (CAG) promoter. The IL-27 carrier AAV vectors and the control vector were compacted with a pAAV-R/C vector (AAV serotype 8 [AAV8]) and an adenoviral helper vector in 293K cells. Viruses were purified with CsCl gradient ultracentrifugation, and the titers of the generated AAV vectors were determined by real-time PCR. The generated AAV-IL-27, AAV-IL-2, and AAV-ctrl vectors were typically with titers of about 1 × 10 13 DRP/ml. The generated AAV vectors were aliquoted and stored at -80°C before use.
Treatment of mice with tumors using AAV. Cancer cells were injected into each C57BL6 or BALB/c mouse s.c. Four days later, mice were treated with AAV-IL-27 or AAV-ctrl vectors diluted in PBS in a total volume of 100 μl, containing 2 × 10 11 DRP of vectors. Viral vectors were injected i.m. into 2 sites of hind legs. The sizes of tumors in each group of mice were measured over time using a digital caliper (Fowler). In some experiments, starting on day 4-5, mice were also treated with 300 μg/mouse of anti-PD-1 or an isotype-matched control antibody i.p. at 3-day intervals for up to 3-4 times. Anti-PD-1 antibody (RMP1-14) and an isotype-matched control antibody (anti-rat IgG2a; 2A3) were purchased from BioXcell. In some experiments, mice were bled and serum IL-27 levels were detected by ELISA (eBiosciences).
Generation of mixed BM chimeric mice and treatment with AAV vectors and/or antibodies. We followed a well-established method as described (37) Generation of B16-GM-CSF cells and mouse immunization. We generated a lentiviral vector expressing GM-CSF by inserting GM-CSF cDNA into an expression vector (plvx-IRES-Zsgreen1; Clontech), which also expresses ZsGreen. Lentivirus expressing GM-CSF or the control Lenivirus (expressing ZsGreen only) was used to infect B16.F10 cells. The resulting cells were sorted based on their expression of ZsGreen using a FACS sorter (Mflo XDP, Beckman Coulter). The ZsGreen + cells that secrete GM-CSF (B16-GM-CSF) or not (B16-ctrl) were injected into mice s.c. for testing tumorigenicity. In some experiments, lethally irradiated (3,000 rads) B16-GM-CSF or B16-ctrl cells were injected into C57BL/6 mice i.p. at a dose of 0.2 × 10 6 / mouse. One week after immunization, mice were challenged with B16.F10 cells (0.2 × 10 6 /mouse) s.c. On day 4 after tumor cell challenge, mice were also treated with AAV-IL-27 or AAV-ctrl virus at a dose of 2 × 10 11 DRP/mouse. Tumor growth and survival were observed as described above. Flow cytometry. FITC-, PE-, APC-, or Percp-labeled antibodies to CD3 (17A2), CD4 (GK1.5), CD8α (53-6.7), CD11b (M1/70), CD11c (N418), CD19 (6D5), CD25 (PC61), CD45 (30-F11), CD45.2 (104), NK1.1 (PK136), I-A/I-E (M5/114.15.2), PD-L1 (MIH5), FoxP3 (NRRF-30), IL-2 (JES6-5H4), IFN-γ (XMG1.2), Granzyme B (GB11), and Perforin (S16009A) and isotype-matched control antibodies were purchased from BD Biosciences (antibodies to CD3, CD4, CD8, CD11b, CD11c, NK1.1, I-A/I-E, Granzyme B, Perforin, IL-2, IFN-g and control antibodies) or eBiosciences (antibodies to CD19, CD25, CD45, CD45.2, PD-L1, FoxP3 and control antibodies). For staining of cell-surface markers, disassociated cells from tumors were stained with various antibodies in staining buffer (PBS with 1% FCS) and incubated on ice for 30 minutes. After washing with staining buffer, cells were fixed in 1% paraformaldehyde in PBS. For intracellular cytokine staining, cells were stimulated in culture medium for 4 hours with 100 ng/ml of PMA and 500 ng/ml of ionomycin in the presence of GolgiStop (1:1,500; BD Biosciences). Viable cells were then fixed in IC fixation buffer (eBioscience), permeabilized with 1× permeabilization buffer (eBioscieces) and stained with respective antibodies to cytokines. Foxp3 staining was performed according to manufacturer's protocol (BD Biosciences). Stained cells were analyzed on a FACSCalibur flow cytometer, and data were analyzed using the flowjo software (Tree Star Inc.).
Peptide synthesis and IFN-γ ELISPOT assay. Recently, the whole-genome sequencing of B16.F10 tumor cells identified 21 mutated tumor antigens (32) . The mutated peptides were synthesized by GL Biochem Ltd. based on the sequences published by Kreiter et al (32) . IFN-γ ELISPOT assays were used to evaluate T cell responses to these peptide antigens. We used an IFN-γ ELISPOT assay kit (Dakewe) and followed the protocol provided in the kit for the assay. Spleen cells from AAV-IL-27/B16-GM-CSF-treated tumor-bearing mice or controls were first depleted of antigen-presenting cells (APC) using rat anti-mouse CD16/CD32 mAb (2.4G2; BD Biosciences) and sheep anti-rat IgG Dyna beads (Thermo Fisher); then, the APC-depleted splenocytes were used as responders (1 × 10 6 /ml), and irradiated spleen cells from naive B6 mice were used as APC (2 × 10 6 /ml). Each peptide was used at a final concentration of 20 μg/ml.
Histology. Mice were sacrificed by CO 2 inhalation. Various organs were removed and fixed in 10% formalin/PBS. Paraffin sections were prepared and stained with H&E in the histology core laboratory in the Department of Pathology and Comprehensive Cancer Center at the Ohio State University. Histological images were photographed using a microscope. Inflammatory lesions in liver sections were counted under a 100× field with a microscope, and 3 random fields were counted for each sample.
Statistics. Two-tailed Student's t tests, 1-way ANOVA, and Mann-Whitney U tests were used for statistical analyses. For comparison of mice survival, Kaplan-Meier survival analyses and log-rank tests were performed. The GraphPad Prism software was used for all the analyses. A P value less than 0.05 was considered significant.
Study approval. All mice works involved in this study were approved by IACUC of the Ohio State University College of Medicine or Shanghai Jiao Tong University School of Medicine. The animal facilities were fully accredited by American Association for Accreditation of Laboratory Animal Care.
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